SCHEDULE 13D/A: Lipella Pharmaceuticals CEO Secures Irrevocable Proxy Over Key Shares, Bolstering Control Amidst Private Placement

Lipella Pharmaceuticals Inc. has filed an amendment to its Schedule 13D, revealing an irrevocable proxy granted by Spartan Capital Securities, LLC to CEO Dr. Jonathan Kaufman, giving him voting control over significant convertible preferred and warrant shares issued in recent agreements and a private placement.

Summary

• Lipella Pharmaceuticals Inc. (the Corporation) has entered into a Consulting Agreement and Placement Agent Agreement with Spartan Capital Securities, LLC (Spartan), dated December 5, 2024, and amended on December 10, 2024.
• Under these agreements, Spartan is to receive up to 1,050,000 shares of Series C Convertible Preferred Stock (Consultant Shares), convertible into up to 1,050,000 shares of Common Stock (Conversion Shares), for advisory and consultant services.
• Spartan will also receive common stock purchase warrants (Warrant Shares) exercisable for a number of shares equal to 10% of the Series B non-voting convertible preferred stock sold in a private placement (the Offering) where Spartan serves as placement agent.
• Spartan has granted an Irrevocable Proxy and Power of Attorney to Dr. Jonathan Kaufman, CEO of Lipella Pharmaceuticals, effective December 20, 2024, giving him full voting power over all Consultant Shares, Conversion Shares, and Warrant Shares held by Spartan and its affiliates (Proxied Shares).
• This irrevocable proxy is a material inducement for Lipella to enter into the Consulting Agreement and Placement Agent Agreement.
• As of February 28, 2025, 441,933 shares of Series C Voting Convertible Preferred Stock (convertible into 441,933 Common Stock) and up to 125,833 Warrant Shares were issued to Spartan and its designee in connection with the private placement closing.
• Dr. Jonathan Kaufman's beneficial ownership of Lipella Common Stock is 212,289 shares, representing 8.0% of the 2,548,811 shares outstanding as of the filing date of Amendment No. 13.
• His beneficial ownership consists of 112,352 shares purchased with personal funds and 99,937 shares from fully vested stock options.
• The Conversion Shares and Warrant Shares subject to the proxy are not currently deemed beneficially owned by Dr. Kaufman because their conversion/exercise is subject to a 4.99% beneficial ownership limitation, preventing acquisition within 60 days.
• The Corporation undertakes to include the maximum possible number of Conversion Shares and Warrant Shares in initial and subsequent registration statements for reoffer and resale.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the document is primarily procedural, it formalizes a significant control mechanism for the CEO and confirms a capital raise (private placement), which are generally positive for company stability and operations. The restrictions on Spartan's shares are a minor negative for Spartan but a positive for company control.

Positives

• The Irrevocable Proxy granted to CEO Dr. Jonathan Kaufman consolidates voting control over a significant block of shares, potentially enhancing leadership stability and strategic alignment.
• The underlying agreements with Spartan Capital Securities, LLC, including a private placement, indicate successful capital raising efforts for the company.
• The company's undertaking to register the Conversion Shares and Warrant Shares for reoffer and resale suggests a commitment to facilitating liquidity for investors in the future.

Negatives

• Spartan Capital Securities, LLC, as the holder of the Proxied Shares, relinquishes voting control to Dr. Jonathan Kaufman, which may limit its influence despite its equity stake.
• Restrictions on the transfer of Consultant Shares, Conversion Shares, and Warrant Shares, requiring prior corporate consent and notice, could limit Spartan's liquidity options until registration for resale occurs.

Risks

• The conversion of Preferred Stock and exercise of Warrants are subject to a beneficial ownership limitation (4.99%), which could restrict the immediate conversion or exercise of all shares by holders.
• Transfer restrictions on the Consultant Shares, Conversion Shares, and Warrant Shares could impact the liquidity and marketability of these securities for Spartan and its Attribution Parties.
• Future registration of Conversion Shares and Warrant Shares for reoffer and resale could lead to market dilution if a large number of shares are sold into the market.

Future Outlook

The Corporation has undertaken to include the maximum possible number of Conversion Shares and Warrant Shares in the initial registration statement filed in connection with the Offering and in each subsequent registration statement, as needed, to facilitate their reoffer and resale. All transfer and notice restrictions on these shares will terminate six months after any issuance if they are not then registered for resale.

Management Comments

• Dr. Jonathan Kaufman, Chief Executive Officer of the Corporation, is appointed as the irrevocable proxy and attorney-in-fact to represent and vote the Proxied Shares held by Spartan and its Attribution Parties.
• Dr. Kaufman's beneficial ownership includes shares purchased with personal funds and shares from fully vested stock options, demonstrating his personal investment in the company.

Industry Context

This filing primarily concerns specific corporate governance and financing arrangements for Lipella Pharmaceuticals Inc., rather than broader industry trends. It reflects a common practice in private placements where placement agents receive equity compensation, and the use of irrevocable proxies can be a mechanism to manage voting control, particularly in smaller or developing public companies.

Corporate Governance

Related Party Transactions

• The Consulting Agreement and Placement Agent Agreement between Lipella Pharmaceuticals Inc. and Spartan Capital Securities, LLC, where Spartan provides services in exchange for equity (Series C Preferred Stock and Warrants).
• The Irrevocable Proxy granted by Spartan Capital Securities, LLC to Dr. Jonathan Kaufman, the CEO of Lipella Pharmaceuticals, over the shares issued to Spartan, formalizing a control arrangement between the company's management and a key service provider/investor.

Stakeholder Impact

• **Shareholders**: Dr. Kaufman's increased voting control may lead to more stable leadership and strategic execution. However, the future registration and potential sale of Conversion and Warrant Shares could lead to dilution.
• **Spartan Capital Securities, LLC**: While receiving equity compensation for services, Spartan's voting rights over those shares are transferred to Dr. Kaufman, and their ability to freely transfer these shares is restricted until registration, impacting their liquidity.
• **Management (Dr. Jonathan Kaufman)**: Gains significant voting power, strengthening his position and ability to guide the company's direction.

Next Steps

• The Corporation undertakes to include the maximum possible number of Conversion Shares and Warrant Shares in the initial registration statement filed in connection with the Offering.
• The Corporation will include these shares in each subsequent registration statement, as needed, for reoffer and resale.
• Transfer and notice restrictions on the Conversion Shares and Warrant Shares will terminate six months after any issuance if they are not then registered for resale.

Key Dates

Keywords

Lipella Pharmaceuticals, SEC filing, Schedule 13D, Irrevocable Proxy, Common Stock, Preferred Stock, Warrants, Beneficial Ownership, Corporate Governance, Jonathan Kaufman, Spartan Capital Securities, Private Placement, Consulting Agreement, Placement Agent Agreement